한국파마

032300KOSDAQ의약품 제조업

52.8 / 100

Reference Date: 2026-07-24

Financial Score16.5 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 6.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanok Pharma focuses on developing and selling prescription drugs for various disease areas such as the central nervous system and circulatory system through its own R&D. It expands its research in biopharmaceuticals and improved drugs via research centers in Daegu and Uijeongbu. Additionally, the company engages in CMO business, producing solid dosage forms and topical solutions, and is expanding its global market through exports and licensing-out deals.

Number of Employees

284people

Average Salary

67.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

1.19Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

-3.77Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

1.87Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼58.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.6% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
정신과용 뇌파진단시스템 공급 확산…와이브레인-한국파마 맞손
한국파마와 와이브레인의 협력으로 정신과용 뇌파진단 시스템 공급이 확대되어 기업의 성장 잠재력이 높아짐.
Positive
한국파마, 와이브레인과 맞손…뇌파진단·전자약 기기 공동사업
한국파마와 와이브레인의 협력으로 뇌파 진단 및 전자약 분야에서의 혁신적인 공동사업이 시작되어 기업의 성장 잠재력이 높아졌다.
Positive
와이브레인-한국파마, 뇌파진단·전자약 국내 사업 힘 모은다
한국파마와 와이브레인의 협력 강화로 중추신경계 치료제 분야에서 국내 시장 점유율 확대 및 해외 진출 가속화 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 7,510Won52-week high 15,06052-week low 7,250

1-month return2.0Point

1m -6.71% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0